

30 - References

References

360 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 References

1. Berman RM, et al. Antidepressant effects of ketamine in depressed patients. *Biol Psychiatry* 2000; 47:351-354.
2. Zarate CA, Jr., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Arch Gen Psychiatry* 2006; 63:856-864.
3. Diazgranados N, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. *Arch Gen Psychiatry* 2010; 67:793-802.
4. Murrough JW, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. *Am J Psychiatry* 2013; 170:1134-1142.
5. Singh JB, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. *Am J Psychiatry* 2016; 173:816-826.
6. Fava M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). *Mol Psychiatry* 2020; 25:1592-1603.
7. Li S, et al. Effects of ketamine and esketamine on preventing postpartum depression after cesarean delivery: a meta-analysis. *J Affect Disord* 2024; 351:720-728.
8. Ma S, et al. Association between esketamine interventions and postpartum depression and analgesia following cesarean delivery: a systematic review and meta-analysis. *Am J Obstet Gynecol MFM* 2024; 6:101241.
9. Wang S, et al. Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial. *BMJ* 2024; 385:e078218.
10. Ren L, et al. Comparative efficacy and tolerability of different anesthetics in electroconvulsive therapy for major depressive disorder: a systematic review and network meta-analysis. *J Psychiatr Res* 2024; 171:116-125.
11. de A Simoes Moreira D, et al. Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: a systematic review and meta-analysis. *J Affect Disord* 2023; 330:227-238.
12. Menon V, et al. Ketamine vs electroconvulsive therapy for major depressive episode: a systematic review and meta-analysis. *JAMA Psychiatry* 2023; 80:639-642.
13. Reif A, et al. Esketamine nasal spray versus quetiapine for treatment-resistant depression. *N Engl J Med* 2023; 389:1298-1309.
14. Lener MS, et al. Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine. *Biol Psychiatry* 2017;

81:886-897.

15. Terao I, et al. Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: a systematic review and network meta-analysis. *J Affect Disord* 2024; 346:49-56.
16. Seshadri A, et al. Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for major depression: a systematic review and meta-analysis. *J Affect Disord* 2024; 356:379-384.
17. Glue P, et al. Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study. *Ther Adv Psychopharmacol* 2020; 10:2045125320922474.
18. Beck K, et al. Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: a systematic review and meta-analysis. *JAMA Netw Open* 2020; 3:e204693.
19. Anderson DJ, et al. Ketamine-induced cystitis: a comprehensive review of the urologic effects of this psychoactive drug. *Health Psychol Res* 2022; 10:38247.
20. Chang M, et al. Ketamine cystitis following ketamine therapy for treatment-resistant depression - case report. *BMC Psychiatry* 2024; 24:9.
21. Loo CK, et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. *Acta Psychiatr Scand* 2016; 134:48-56.
22. George D, et al. Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression. *Am J Geriatr Psychiatry* 2017; 25:1199-1209.
23. Glue P, et al. Dose- and exposure-response to ketamine in depression. *Biol Psychiatry* 2011; 70:e9-e10; author reply e11-e12.
24. Cusin C, et al. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. *Am J Psychiatry* 2012; 169:868-869.
25. Arabzadeh S, et al. Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial. *J Affect Disord* 2018; 235:236-241.
26. Domany Y, et al. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study. *Br J Psychiatry* 2019; 214:20-26.
27. Rosenblat JD, et al. Oral ketamine for depression: a systematic review. *J Clin Psychiatry* 2019; 80:18r12475.
28. Swainson J, et al. Sublingual ketamine: an option for increasing accessibility of ketamine treatments for depression? *J Clin Psychiatry* 2020; 81:19r13146.
29. Nguyen L, et al. Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review. *Neuropsychiatr Dis Treat* 2015; 11:2667-2673.
30. Lara DR, et al. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. *Int J Neuropsychopharmacol* 2013; 16:2111-2117.

Depression and anxiety disorders CHAPTER 3 31. Canuso CM, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. *Am J*

Psychiatry 2018; 175:620–630. 32. Daly EJ, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. *JAMA Psychiatry* 2018; 75:139–148. 33. Popova V, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. *Am J Psychiatry* 2019; 176:428–438. 34. Daly EJ, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. *JAMA Psychiatry* 2019; 76:893–903.

Revision #1

Created 2026-01-04 20:15:24 UTC by Omar Ayman

Updated 2026-01-04 20:15:24 UTC by Omar Ayman